Galecto IncNASDAQ:GLTO
- LAST PRICE5.3000
- TODAY'S CHANGE (%)-0.2100 (-3.8113%)
- Bid / Lots5.3500/ 2
- Ask / Lots5.6900/ 5
- Open / Previous Close5.5100 / 5.5100
- Day Range
- 52 Week Range
- Volume29,074
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GLTO |
|---|---|---|
| 09:32 ET | 115 | 5.51 |
| 11:03 ET | 363 | 5.775 |
| 11:05 ET | 100 | 5.78 |
| 11:12 ET | 400 | 5.56 |
| 11:18 ET | 700 | 5.56 |
| 11:20 ET | 100 | 5.75 |
| 11:21 ET | 400 | 5.7 |
| 11:23 ET | 300 | 5.53 |
| 11:25 ET | 100 | 5.51 |
| 11:27 ET | 406 | 5.5 |
| 11:39 ET | 100 | 5.49 |
| 11:52 ET | 100 | 5.51 |
| 12:28 ET | 200 | 5.6152 |
| 12:42 ET | 100 | 5.55 |
| 12:44 ET | 510 | 5.52 |
| 12:48 ET | 100 | 5.51 |
| 12:57 ET | 400 | 5.4 |
| 01:00 ET | 723 | 5.3 |
Nov 1, 2024
Galecto Reports Third Quarter 2024 Financial Results, from 8:30AM ET on Friday Nov 01, 2024 by Dow Jones
8:30AM ET on Friday Nov 01, 2024 by Dow JonesPress Release: Galecto Reports Third Quarter 2024 Financial Results, from 8:30AM ET on Friday Nov 01, 2024 by Dow Jones
8:30AM ET on Friday Nov 01, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Galecto Inc | 7.3M | -0.3x | --- |
Mosaic Immunoengineering Inc | 7.2M | -6.8x | --- |
Klotho Neurosciences Inc | 7.2M | -1.6x | --- |
Alterola Biotech Inc | 7.3M | -3.0x | --- |
Edesa Biotech Inc | 7.5M | -1.1x | --- |
Purple Biotech Ltd | 6.8M | 0.0x | --- |
Company Information
Galecto, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel treatments for cancer and liver diseases. The Company’s pipeline consists small molecule drug candidates that target cancer and fibrosis signaling pathways, including an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications; and a preclinical dual inhibitor of ENL-YEATS and FLT3 (BRM-1420) for multiple genetic subsets of acute myeloid leukemia (AML). The GB1211, is also being developed for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.
Contact Information
- Headquarters
- 75 State Street, Suite 100BOSTON, MA, United States 02109
- Phone
- ---
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Carl Goldfischer
- President, Chief Executive Officer, Director
- Hans Schambye
- Chief Financial Officer
- Jonathan Freve
- Chief Operating Officer
- Anders Pedersen
- General Counsel, Corporate Secretary
- Garrett Winslow
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $7.3M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 1.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.17 |
EPS | $-19.33 |
Book Value | $29.81 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
